01—Abstract
Summary
Summary of the 10-K filed February 23, 2021. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation's (BSX) 2020 Form 10-K filing reveals a challenging year impacted by the COVID-19 pandemic, which led to a 7.7% decrease in net sales, reaching $9.91 billiona.
The company reported a net loss of $82 millionb for the year. Despite the revenue decline, BSX demonstrated resilience through strategic cost management and a focus on its core product franchises across MedSurg, Rhythm and Neuro, and Cardiovascular segments. The company continues to invest in research and development to drive innovation and maintain its competitive edge in the medical device market.
Key strategic imperatives include strengthening category leadership and expanding into high-growth adjacencies. BSX also made progress in its sustainability initiatives and diversity, equity, and inclusion efforts, underscoring its commitment to corporate social responsibility. The divestiture of its Specialty Pharmaceuticals business is planned for the first half of 2021, aiming to streamline operations and focus on its core medical device portfolio.
02—Key points
Key Highlights
- Net sales decreased by 7.7% to $9.91 billion in 2020 compared to 2019, primarily due to the impact of the COVID-19 pandemic on elective procedures.
- The company reported a net loss of $82 million for 2020, a significant decrease from the net income of $4.70 billion reported in 2019, which included substantial tax benefits.
- Boston Scientific repurchased approximately $535 million of its common stock in Q4 2020 under its existing share repurchase program, demonstrating a commitment to returning capital to shareholders.
- The company's product portfolio is diversified across three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular, with significant product lines in each.
- Acquisitions continue to be a part of the company's strategy, with recent acquisitions like BTG plc and Vertiflex, Inc. contributing to its portfolio.
- The company is committed to R&D, focusing on developing next-generation products and technologies to maintain its competitive position in the medical device industry.
- BSX is divesting its Specialty Pharmaceuticals business, expecting the transaction to close in the first half of 2021, which is anticipated to simplify its business structure.
- The company faced operational challenges due to COVID-19, including manufacturing cost impacts from low production levels, but aims to return to normalized production levels.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2020, Boston Scientific Corp lost $0.01.
- Revenue$9.91B100.0%
- Cost of revenue−$3.46B35.0%
- Gross profit$6.45B65.0%
- Operating costs−$6.53B65.9%
- Operating income−$80.0M0.8%
- Interest, other & tax−$2.0M0.0%
- Net income−$82.0M0.8%
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 23, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $9.91B$10.73B | −7.7% |
| Cost of Revenue | $3.46B$3.12B | +11.2% |
| Gross Profit | $6.45B$7.62B | −15.4% |
| SG&A Expenses | $3.79B$3.94B | −3.9% |
| Operating Expenses | $6.53B$6.10B | +7.0% |
| Operating Income | -$80.00M$1.52B | −105.3% |
| Interest Expense | $361.00M$473.00M | −23.7% |
| Net Income | -$82.00M$4.70B | −101.7% |
| EPS (Basic) | $-0.08$3.38 | −102.4% |
| EPS (Diluted) | $-0.08$3.33 | −102.4% |
| Shares Outstanding (Basic) | 1.42B1.39B | +1.8% |
| Shares Outstanding (Diluted) | 1.42B1.41B | +0.4% |
05—Questions
Frequently Asked Questions
How did the COVID-19 pandemic impact Boston Scientific's financial performance in 2020?
The COVID-19 pandemic significantly impacted Boston Scientific's financial performance in 2020. Net sales decreased by 7.7% to $9.91 billion due to the postponement of elective and semi-emergent medical procedures. The company also experienced higher operating expenses as a percentage of net sales and unfavorable gross profit margins due to manufacturing costs associated with reduced production levels.
What is Boston Scientific's strategy regarding acquisitions and divestitures?
Boston Scientific continues to pursue strategic acquisitions to expand its product portfolio and market presence. In 2019, it acquired BTG plc and Vertiflex, Inc. Concurrently, the company is divesting its Specialty Pharmaceuticals business, with the transaction expected to close in the first half of 2021, to focus resources on its core medical device segments.
What is the company's outlook on returning capital to shareholders?
In the fourth quarter of 2020, Boston Scientific repurchased approximately $535 million of its common stock, indicating a commitment to capital return. The company did not pay cash dividends in 2020 but may consider doing so in the future, although there is no assurance.
How is Boston Scientific managing its debt and financial position?
As of December 31, 2020, Boston Scientific had total debt of $9.14 billion and $1.73 billion in cash and cash equivalents. The company took proactive steps in response to the COVID-19 pandemic to manage liquidity, including reducing costs, amending financial covenants, and slowing planned capital expenditures. It maintained compliance with its financial covenants throughout the year.
06—Continue